Drugs / PrimePro
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04573270 | Apr → Aug 2020 | COVID-19 | Thomas Advanced Medical LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04684602 | Jul 2020 → Jul 2030 expected | autoimmune disease, cardiovascular disorder, integumentary system disorder, lung disorder +5 | Thomas Advanced Medical LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PrimePro | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04573270 ↗ |
| Modality | Cell therapy | “single mesenchymal stem cell injection” NCT04573270 ↗ |
| Route | Intravenous | “Intravenous Injection” NCT04573270 ↗ |